A Phase I Study of GDC-0919 for Adult Patients With Recurrent Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 May 2017
At a glance
- Drugs Navoximod (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Genentech; NewLink Genetics Corporation
- 10 May 2017 According to a NewLink Genetics media release, data from this study will be presented at the 2017 ASCO Annual Meeting.
- 02 Feb 2017 Status changed from recruiting to completed.
- 01 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History